Selection of the key articles and interviews published during the 2019 San Antonio Breast Cancer Symposium (SABCS)

The oncoXchange news team spent 4 hectic days in San Antonio, Texas publishing articles and recording interviews with a number of key opinion leaders who presented important new data during the symposium. Here is a selection of some of the most noteworthy news items.

New HER2 Antibody-drug Conjugate Yielded Promising Clinical Responses in Breast Cancer Patients Pre-treated with T-DM1

Interview with: Ian E. Krop, MD, PhD

Polygenic Breast Cancer Risk Modification in carriers of High and intermediate Risk gene Mutations

Interview with Allison W. Kurian, MD, MSc

Activity of HER2 antibody-drug conjugate promising in breast cancer pretreated with T-DM1

Article by Wayne Kuznar for oncoXchange

KEYNOTE-522 - Neoadjuvant and Adjuvant Treatment with Pembrolizumab Improves PCR for TNBC

Interview with Peter Schmid, MD, PhD

Combining Atezolizumab with Neoadjuvant Chemotherapy Does Not Improve Pathologic Complete Response Rates for Patients with Triple-Negative Breast Cancer

Interview with Luca Gianni, MD

Ribociclib/letrozole has high biological activity in luminal B breast cancer (CORALLEEN trial from SOLTI research group)

Article by Wayne Kuznar for oncoXchange